Cargando…
Lung CCR6(−)CXCR3(−) type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases
Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the deterioration of lung function. The aim of this study was to i...
Autores principales: | Tsukuda, Tsukie Kin, Ohnishi, Hiroshi, Fujimoto, Minoru, Nakatani, Yu, Takamatsu, Kazufumi, Naka, Tetsuji, Yokoyama, Akihito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666512/ https://www.ncbi.nlm.nih.gov/pubmed/36380088 http://dx.doi.org/10.1038/s41598-022-24011-0 |
Ejemplares similares
-
Air Pericardial Tamponade Caused by Lung Cancer
por: Takamatsu, Kazufumi, et al.
Publicado: (2020) -
Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020) -
Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019) -
The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022) -
Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)